AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID

First Posted Date: 2017-09-08

Last Posted Date: 2019-07-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT03276078

Locations: 🇨🇳
Research Site, Changchun, China

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Aclidinium Bromide 400 μg

First Posted Date: 2017-09-08

Last Posted Date: 2023-12-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT03276052

Locations: 🇨🇳
Research Site, Chengdu, China

To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Abediterol

First Posted Date: 2017-09-06

Last Posted Date: 2017-11-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT03273127

Locations: 🇩🇪
Research Site, Berlin, Germany

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: MEDI1341

First Posted Date: 2017-09-05

Last Posted Date: 2022-06-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 50

Registration Number: NCT03272165

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Phase 1

Completed

Conditions: High Risk Myelodysplastic Syndrome
T-cell Non-Hodgkin Lymphoma
Relapsed or Refractory Haematological Malignancies Including
Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Chronic Myelomonocytic Leukemia
Richter's Syndrome
B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: AZD4573

First Posted Date: 2017-08-28

Last Posted Date: 2021-10-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT03263637

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Conditions: NF type1 With Inoperable Plexiform Neurofibromas

First Posted Date: 2017-08-24

Last Posted Date: 2020-05-01

Lead Sponsor: AstraZeneca

Registration Number: NCT03259633

Locations: 🇺🇸
Research Site, New Orleans, Louisiana, United States

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: AZD6094 200 mg
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2017-08-23

Last Posted Date: 2020-02-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 45

Registration Number: NCT03258515

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Phase 2

Completed

Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib

First Posted Date: 2017-08-04

Last Posted Date: 2024-10-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 154

Registration Number: NCT03239340

Locations: 🇪🇸
Research Site, Sevilla, Spain

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Phase 1

Completed

Conditions: Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Interventions: Drug: Standard Arm - Fulvestrant
Drug: AZD9496

First Posted Date: 2017-08-02

Last Posted Date: 2020-02-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 49

Registration Number: NCT03236974

Locations: 🇬🇧
Research Site, Sutton In Ashfield, United Kingdom

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MEDI0382 high dose
Drug: Placebo
Drug: MEDI0382 low dose
Drug: MEDI0382 mid dose
Drug: Liraglutide

First Posted Date: 2017-08-01

Last Posted Date: 2020-08-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 834

Registration Number: NCT03235050

Locations: 🇸🇰
Research Site, Zilina, Slovakia

Home Terms & Conditions Privacy Policy